Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,063 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam.
Rodríguez-Núñez O, Periañez-Parraga L, Oliver A, Munita JM, Boté A, Gasch O, Nuvials X, Dinh A, Shaw R, Lomas JM, Torres V, Castón J, Araos R, Abbo LM, Rakita R, Pérez F, Aitken SL, Arias CA, Martín-Pena ML, Colomar A, Núñez MB, Mensa J, Martínez JA, Soriano A. Rodríguez-Núñez O, et al. Among authors: torres v. Open Forum Infect Dis. 2019 Sep 28;6(10):ofz416. doi: 10.1093/ofid/ofz416. eCollection 2019 Oct. Open Forum Infect Dis. 2019. PMID: 31660373 Free PMC article.
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
Díaz-Cañestro M, Periañez L, Mulet X, Martin-Pena ML, Fraile-Ribot PA, Ayestarán I, Colomar A, Nuñez B, Maciá M, Novo A, Torres V, Asensio J, López-Causapé C, Delgado O, Pérez JL, Murillas J, Riera M, Oliver A. Díaz-Cañestro M, et al. Among authors: torres v. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2191-2200. doi: 10.1007/s10096-018-3361-0. Epub 2018 Aug 23. Eur J Clin Microbiol Infect Dis. 2018. PMID: 30141088
Individualised perioperative open-lung approach versus standard protective ventilation in abdominal surgery (iPROVE): a randomised controlled trial.
Ferrando C, Soro M, Unzueta C, Suarez-Sipmann F, Canet J, Librero J, Pozo N, Peiró S, Llombart A, León I, India I, Aldecoa C, Díaz-Cambronero O, Pestaña D, Redondo FJ, Garutti I, Balust J, García JI, Ibáñez M, Granell M, Rodríguez A, Gallego L, de la Matta M, Gonzalez R, Brunelli A, García J, Rovira L, Barrios F, Torres V, Hernández S, Gracia E, Giné M, García M, García N, Miguel L, Sánchez S, Piñeiro P, Pujol R, García-Del-Valle S, Valdivia J, Hernández MJ, Padrón O, Colás A, Puig J, Azparren G, Tusman G, Villar J, Belda J; Individualized PeRioperative Open-lung VEntilation (iPROVE) Network. Ferrando C, et al. Among authors: torres v. Lancet Respir Med. 2018 Mar;6(3):193-203. doi: 10.1016/S2213-2600(18)30024-9. Epub 2018 Jan 19. Lancet Respir Med. 2018. PMID: 29371130 Clinical Trial.
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium. Meijer E, et al. Am J Kidney Dis. 2014 Mar;63(3):446-55. doi: 10.1053/j.ajkd.2013.10.011. Epub 2013 Dec 15. Am J Kidney Dis. 2014. PMID: 24342522 Free PMC article. Clinical Trial.
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.
Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett WM, Meyers CM, Thompson PA, Miller JP; CRISP Consortium. Rule AD, et al. J Am Soc Nephrol. 2006 Mar;17(3):854-62. doi: 10.1681/ASN.2005070697. Epub 2006 Feb 1. J Am Soc Nephrol. 2006. PMID: 16452494
Volume progression in polycystic kidney disease.
Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators. Grantham JJ, et al. N Engl J Med. 2006 May 18;354(20):2122-30. doi: 10.1056/NEJMoa054341. N Engl J Med. 2006. PMID: 16707749 Free article.
Autosomal dominant polycystic kidney disease.
Torres VE, Harris PC, Pirson Y. Torres VE, et al. Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1. Lancet. 2007. PMID: 17434405 Review.
1,063 results